LOSARTAN AS AN ENHANCER OF MYSCLE TISSUE PERFUSION IN ELDERLY: A PILOT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项先导性研究的目的是确定FDA批准的血管扩张剂氯沙坦是否能增强老年男性和女性的肌肉组织灌注量。这项先导性研究的数据将被用作重新提交谢菲尔德-摩尔博士的NIH/NIA R01竞争续签的初步数据。 我们假设，氯沙坦是一种常见的血管扩张剂，可以增强老年人的肌肉组织灌注量。这个试点项目的目标是确定洛沙坦，一种FDA批准的血管扩张剂和肾素-血管紧张素-醛固酮系统的抑制剂，是否可以强烈地刺激老年人的肌肉组织灌流(通过对比增强超声测量)。受试者将接受50毫克的氯沙坦治疗，随后是多普勒和CEU。这项先导性研究的结果将在很大程度上让评审者相信，氯沙坦能够增强肌肉组织的灌注量，从而促进氨基酸等营养物质的交换。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this pilot study is to determine whether Losartan, an FDA approved vasodilator, enhances muscle tissue perfusion in older men and women. Data from this pilot study will be used as preliminary data for resubmission of Dr. Sheffield-Moore's NIH/NIA R01 Competitive renewal. We hypothesize that Losartan, a common vasodilator, can enhance muscle tissue perfusion in the elderly. The goal of this pilot project is to determine whether Losartan, an FDA approved vasodilator and an inhibitor of the renin-angiotensin-aldosterone system, can acutely stimulate muscle tissue perfusion in elderly (as measured with contrast enhanced ultrasound). Subjects will be administered 50mg of Losartan with Doppler and CEU to follow. Results from this pilot study will go a long way to convince reviewers that Losartan is capable of enhancing muscle tissue perfusion, and thus facilitating the nutritive exchange of nutrients such as amino acids.